Abstract
Heart ion-channel function and expression are continuously being regulated on the basis of the hemodynamic state of the cardiovascular system, the neurohumoral milieu and the properties of the ongoing ionic fluxes. These homeostatic forces act through multiple mechanisms at transcriptional, translational and post-translational levels. Of clinical importance is the fact that with adverse stress these regulatory mechanisms can produce arrhythmogenic channel remodelling. Although a great deal is known about the functionality of ion channels and the generation of the action potential, much less is known about the underlying controlling mechanisms and how these become derailed during disease. microRNA-mediated posttranscriptional control is a very recent addition to cardiovascular biology. Here, we outline discoveries pertaining to these new regulators and how they might be involved in cardiac electrophysiology and pathology.
Keywords: microRNA, cardiac electrophysiology, ion channels, arrhythmogenesis, conduction
Current Drug Targets
Title: MicroRNAs and Cardiac Conduction
Volume: 11 Issue: 8
Author(s): M.V.G. Latronico and G. Condorelli
Affiliation:
Keywords: microRNA, cardiac electrophysiology, ion channels, arrhythmogenesis, conduction
Abstract: Heart ion-channel function and expression are continuously being regulated on the basis of the hemodynamic state of the cardiovascular system, the neurohumoral milieu and the properties of the ongoing ionic fluxes. These homeostatic forces act through multiple mechanisms at transcriptional, translational and post-translational levels. Of clinical importance is the fact that with adverse stress these regulatory mechanisms can produce arrhythmogenic channel remodelling. Although a great deal is known about the functionality of ion channels and the generation of the action potential, much less is known about the underlying controlling mechanisms and how these become derailed during disease. microRNA-mediated posttranscriptional control is a very recent addition to cardiovascular biology. Here, we outline discoveries pertaining to these new regulators and how they might be involved in cardiac electrophysiology and pathology.
Export Options
About this article
Cite this article as:
Latronico M.V.G. and Condorelli G., MicroRNAs and Cardiac Conduction, Current Drug Targets 2010; 11 (8) . https://dx.doi.org/10.2174/138945010791591340
DOI https://dx.doi.org/10.2174/138945010791591340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Effect of SDF-1 α on Endogenous Mobilized and Transplanted Stem Cells in Regeneration after Myocardial Infarction
Current Pharmaceutical Design Exercise-induced Physiological Hypertrophy: Insights from Genomics
Current Genomics Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Effects of Endothelins on Cardiac and Vascular Cells: New Therapeutic Target for the Future?
Current Vascular Pharmacology Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Electrocardiographic Abnormalities in Thalassemia Patients with Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design LCHAD and MTP Deficiencies - Two Disorders of Mitochondrial Fatty Acid β-Oxidation with Unusual Features
Current Pediatric Reviews Stem Cell Engineering for the Treatment of Severe Hemoglobinopathies
Current Molecular Medicine Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Potential Roles of MyomiRs in Cardiac Development and Related Diseases
Current Cardiology Reviews